MedTrace Logo

Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss

NCT06501924 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 516

Last updated 2024-12-19

No results posted yet for this study

Summary

The primary objective of the study is to assess the safety and efficacy of DA-005 and DA-002 as a treatment for hair loss (androgenetic alopecia).

Conditions

Interventions

DIETARY_SUPPLEMENT

DA-005

Oral Botanical Supplement HIF-1a inhibitor

DRUG

Topical minoxidil 5%

Topical minoxidil 5%

DRUG

DA-002

Topical Alpha 1 Agonist (GRAS)

DIETARY_SUPPLEMENT

Placebo Oral Tablet

Placebo Oral Tablet

OTHER

Placebo Topical Solution

Placebo Topical Solution

Sponsors & Collaborators

  • Follea International Limited

    collaborator INDUSTRY

  • Daniel Alain, Inc.

    collaborator UNKNOWN

  • Applied Biology, Inc.

    lead INDUSTRY

Principal Investigators

  • Andy Goren, MD · University of Rome G. Marconi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-15
Primary Completion
2025-10-17
Completion
2025-12-12

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06501924 on ClinicalTrials.gov